Examining HER2 Expression in Prostate Cancer Patients
Single Center Registration Study on HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer.
This study looks at the HER2 protein in prostate cancer patients to see how its levels relate to their age and cancer characteristics, helping us understand its impact on treatment and disease progression.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 50 Years to 90 Years |
| Sex | Male |
| Sponsor | Qilu Hospital of Shandong University Academic / other |
| Locations | 1 site (Jinan, Shandong) |
| Trial ID | NCT06146114 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the expression of HER2 protein in prostate cancer patients at Qilu Hospital of Shandong University. It involves a retrospective analysis of tumor tissue collected from patients diagnosed between January 2018 and July 2023. The study aims to correlate HER2 expression levels with various clinical and pathological characteristics, such as age and TNM grade, to better understand its implications for disease progression and treatment outcomes.
Who should consider this trial
Good fit: Ideal candidates include men aged 18 and older with histopathologically confirmed prostate cancer who were treated at Qilu Hospital during the study period.
Not a fit: Patients with other active malignancies or those deemed unsuitable by the researchers may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the role of HER2 in prostate cancer, potentially guiding more personalized treatment strategies.
How similar studies have performed: While studies on HER2 expression in other cancers have shown promise, this specific investigation into prostate cancer is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1. Prostate cancer patients confirmed by histopathology in our hospital from January 2018 to July 2023; 2. Men aged ≥ 18 years old; 3. The expected survival time is greater than 12 weeks; 4. The KPS functional status score is greater than 60, and the ECOG status score is 0-2 points; 5. The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up. Exclusion Criteria: - 1. Those who have been diagnosed with tumors in other parts, such as lung cancer, liver cancer, stomach cancer, colorectal cancer, breast cancer, etc. (except for cancer in situ or non melanoma skin cancer, or combined tumors with low recurrence probability within a few years); 2. According to the researcher's judgment, there are other patients who are not suitable for inclusion.
Where this trial is running
Jinan, Shandong
- Qilu hospital — Jinan, Shandong, China (Recruiting)
Study contacts
- Study coordinator: yong wang, dcotor
- Email: bkang68@sdu.edu.cn
- Phone: 18560084850
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.